Literature DB >> 30176965

CPAP Therapy Delays Cardiovagal Reactivation and Decreases Arterial Renin-Angiotensin System Activity in Humans With Obstructive Sleep Apnea.

David D M Nicholl1,2, Patrick J Hanly1,3,4, Ann A Zalucky1,2, Michelle C Mann1,2, Jennifer M MacRae1,2,5, Marc J Poulin2,4,6,7,8, George B Handley9, Darlene Y Sola1,2, Sofia B Ahmed1,2,5.   

Abstract

STUDY
OBJECTIVES: Obstructive sleep apnea (OSA) is associated with increased cardiovascular risk. The effect of OSA treatment with continuous positive airway pressure (CPAP) on the cardiovascular response to a stressor is unknown. We sought to determine the effect of CPAP therapy on heart rate variability (HRV) and arterial stiffness, at baseline, in response to, and recovery from a physiological stressor, Angiotensin II (AngII), in humans with OSA.
METHODS: Twenty-five incident healthy subjects (32% female; 49 ± 2 years) with moderate-severe OSA and nocturnal hypoxia were studied in high-salt balance, a state of maximal renin-angiotensin system (RAS) suppression, before CPAP, and after 4 weeks of effective CPAP therapy (usage > 4 h/night) in a second identical study day. HRV was calculated by spectral power and time domain analysis. Aortic augmentation index (AIx) and carotid-femoral pulse-wave velocity (PWVcf) were measured by applanation tonometry. HRV and arterial stiffness were measured at baseline and in response to AngII challenge (3 ng/ kg/min·30 minutes, 6 ng/kg/min·30 minutes, recovery·30 minutes). The primary outcome was the association between CPAP treatment and HRV and arterial stiffness responses to, and recovery from, AngII challenge. In an exploratory analysis subjects were stratified by sex.
RESULTS: CPAP corrected OSA and nocturnal hypoxemia. CPAP treatment was associated with increased sensitivity and delayed recovery from AngII (Δln HF [high frequency; recovery: -0.09 ± 0.19 versus -0.59 ± 0.17 ms2, P = .042; ΔrMSSD [root mean successive differences; recovery: -0.4 ± 2.0 versus -7.2 ± 1.9 ms, P = .001], ΔpNN50 [percentage of normal waves differing ≥ 50 ms compared to the preceding wave; AngII: 1.3 ± 2.3 versus -3.0 ± 2.4%, P = .043; recovery: -0.4 ± 1.4 versus -6.0 ± 1.9%, P = .001], all values pre-CPAP versus post-CPAP treatment). No differences were observed by sex. There was increased AIx sensitivity to AngII after CPAP among men (8.2 ± 1.7 versus 11.9 ± 2.2%, P = .046), but not women (11.4 ± 1.5 versus 11.6 ± 2.1%, P = .4). No change in PWVcf sensitivity was observed in either sex.
CONCLUSIONS: CPAP therapy was associated with delayed cardiovagal reactivation after a stressor and down-regulation of the arterial RAS. These findings may have important implications in mitigating cardiovascular risk in both men and women with OSA.
© 2018 American Academy of Sleep Medicine.

Entities:  

Keywords:  arterial stiffness; continuous positive airway pressure; heart rate variability; obstructive sleep apnea; renin-angiotensin system

Mesh:

Year:  2018        PMID: 30176965      PMCID: PMC6134233          DOI: 10.5664/jcsm.7326

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN: 1550-9389            Impact factor:   4.062


  55 in total

1.  Mortality in severe sleep apnoea/hypopnoea syndrome patients: impact of treatment.

Authors:  S Marti; G Sampol; X Muñoz; F Torres; A Roca; P Lloberes; T Sagalés; P Quesada; F Morell
Journal:  Eur Respir J       Date:  2002-12       Impact factor: 16.671

2.  Effects of continuous positive airway pressure treatment and withdrawal in patients with obstructive sleep apnea on arterial stiffness and central BP.

Authors:  Craig L Phillips; Brendon Yee; Qiao Yang; Anna Tessa Villaneuva; Jan Hedner; Norbert Berend; Ronald Grunstein
Journal:  Chest       Date:  2008-03-17       Impact factor: 9.410

3.  Variation in the renin angiotensin system throughout the normal menstrual cycle.

Authors:  Mala Chidambaram; John A Duncan; Vesta S Lai; Daniel C Cattran; John S Floras; James W Scholey; Judith A Miller
Journal:  J Am Soc Nephrol       Date:  2002-02       Impact factor: 10.121

4.  Gender differences in the renal response to renin-angiotensin system blockade.

Authors:  Judith A Miller; David Z Cherney; John A Duncan; Vesta Lai; Kevin D Burns; Christopher R J Kennedy; Joseph Zimpelmann; Wei Gao; Daniel C Cattran; James W Scholey
Journal:  J Am Soc Nephrol       Date:  2006-08-16       Impact factor: 10.121

Review 5.  Meta-Analysis of Cardiovascular Outcomes With Continuous Positive Airway Pressure Therapy in Patients With Obstructive Sleep Apnea.

Authors:  Ahmed S Abuzaid; Haitham S Al Ashry; Ayman Elbadawi; Ha Ld; Marwan Saad; Islam Y Elgendy; Akram Elgendy; Ahmed N Mahmoud; Amgad Mentias; Amr Barakat; Chitra Lal
Journal:  Am J Cardiol       Date:  2017-06-01       Impact factor: 2.778

6.  Cardiovascular mortality in women with obstructive sleep apnea with or without continuous positive airway pressure treatment: a cohort study.

Authors:  Francisco Campos-Rodriguez; Miguel A Martinez-Garcia; Ines de la Cruz-Moron; Carmen Almeida-Gonzalez; Pablo Catalan-Serra; Josep M Montserrat
Journal:  Ann Intern Med       Date:  2012-01-17       Impact factor: 25.391

7.  Continuous positive airway pressure therapy lowers vagal tone in patients with obstructive sleep apnoea-hypopnoea syndrome.

Authors:  Stavros I Chrysostomakis; Emmanuel N Simantirakis; Sophia E Schiza; Ioannis K Karalis; Nikolaos C Klapsinos; Nikolaos M Siafakas; Panos E Vardas
Journal:  Hellenic J Cardiol       Date:  2006 Jan-Feb

8.  The occurrence of sleep-disordered breathing among middle-aged adults.

Authors:  T Young; M Palta; J Dempsey; J Skatrud; S Weber; S Badr
Journal:  N Engl J Med       Date:  1993-04-29       Impact factor: 91.245

9.  Time course and effect of sodium intake on vascular and hormonal responses to enalapril (MK 421) in normal subjects.

Authors:  D M Shoback; G H Williams; S L Swartz; R O Davies; N K Hollenberg
Journal:  J Cardiovasc Pharmacol       Date:  1983 Nov-Dec       Impact factor: 3.105

10.  Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine.

Authors:  Nancy A Collop; W McDowell Anderson; Brian Boehlecke; David Claman; Rochelle Goldberg; Daniel J Gottlieb; David Hudgel; Michael Sateia; Richard Schwab
Journal:  J Clin Sleep Med       Date:  2007-12-15       Impact factor: 4.062

View more
  5 in total

Review 1.  Efficacy of continuous positive airway pressure on subcutaneous adipose tissue in patients with obstructive sleep apnea: a meta-analysis of randomized controlled trials.

Authors:  Yibin Liu; Chaowei Li; Chunchun Wu; Ping Li; Yunan Su; Qingshi Chen
Journal:  Sleep Breath       Date:  2020-04-24       Impact factor: 2.816

2.  Heart rate variability during wakefulness as a marker of obstructive sleep apnea severity.

Authors:  Hua Qin; Brendan T Keenan; Diego R Mazzotti; Fernando Vaquerizo-Villar; Jan F Kraemer; Niels Wessel; Sergio Tufik; Lia Bittencourt; Peter A Cistulli; Philip de Chazal; Kate Sutherland; Bhajan Singh; Allan I Pack; Ning-Hung Chen; Ingo Fietze; Thorarinn Gislason; Steven Holfinger; Ulysses J Magalang; Thomas Penzel
Journal:  Sleep       Date:  2021-05-14       Impact factor: 5.849

3.  Putative contributions of circadian clock and sleep in the context of SARS-CoV-2 infection.

Authors:  Miguel Meira E Cruz; Masaaki Miyazawa; David Gozal
Journal:  Eur Respir J       Date:  2020-06-04       Impact factor: 16.671

4.  O‑GlcNAcylation contributes to intermittent hypoxia‑associated vascular dysfunction via modulation of MAPKs but not CaMKII pathways.

Authors:  Xueling Guo; Yan Deng; Linghui Zhan; Jin Shang; Huiguo Liu
Journal:  Mol Med Rep       Date:  2021-08-26       Impact factor: 2.952

5.  Meta-analysis of changes in the levels of catecholamines and blood pressure with continuous positive airway pressure therapy in obstructive sleep apnea.

Authors:  Mackenzie Green; Gie Ken-Dror; David Fluck; Charif Sada; Pankaj Sharma; Christopher H Fry; Thang S Han
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-09-24       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.